Short Interest in abrdn Life Sciences Investors (NYSE:HQL) Declines By 60.1%

abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 14,265 shares, a decrease of 60.1% from the June 15th total of 35,781 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 150,344 shares, the days-to-cover ratio is currently 0.1 days.

abrdn Life Sciences Investors Price Performance

NYSE:HQL traded up $0.18 during mid-day trading on Wednesday, reaching $20.11. 88,208 shares of the stock were exchanged, compared to its average volume of 121,472. abrdn Life Sciences Investors has a 1-year low of $12.94 and a 1-year high of $21.32. The business has a fifty day moving average price of $18.28 and a 200 day moving average price of $17.39.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Thursday, May 21st were issued a dividend of $0.56 per share. This represents a $2.24 dividend on an annualized basis and a yield of 11.1%. The ex-dividend date was Thursday, May 21st.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several large investors have recently modified their holdings of HQL. Closed End Fund Advisors Inc. acquired a new position in shares of abrdn Life Sciences Investors in the 4th quarter valued at $498,000. Formidable Asset Management LLC lifted its stake in abrdn Life Sciences Investors by 27.3% during the first quarter. Formidable Asset Management LLC now owns 158,385 shares of the company’s stock valued at $2,658,000 after buying an additional 33,940 shares in the last quarter. Absolute Investment Advisers LLC purchased a new stake in abrdn Life Sciences Investors during the first quarter valued at about $582,000. Uhlmann Price Securities LLC boosted its holdings in shares of abrdn Life Sciences Investors by 2.3% in the first quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock worth $1,267,000 after buying an additional 1,719 shares during the period. Finally, World Investment Advisors increased its position in shares of abrdn Life Sciences Investors by 7.2% in the fourth quarter. World Investment Advisors now owns 99,520 shares of the company’s stock worth $1,670,000 after acquiring an additional 6,654 shares in the last quarter. 32.21% of the stock is owned by institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.